Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

BACKGROUND Alterations of the HER2 (also known as erbB-2 or neu) proto-oncogene have been implicated in the carcinogenesis and prognosis of breast cancer. A polymorphism at codon 655 (GTC/valine to ATC /isoleucine [Val(655)Ile]) in the transmembrane domain-coding region of this gene has been identified and may be associated with the risk of breast cancer. We evaluated this hypothesis in a subgroup of women who participated in a large-scale, population-based, case-control study of breast cancer in Shanghai, China. METHODS Genomic DNA from 339 patients with breast cancer and 361 healthy control subjects was examined for the Val(655)Ile polymorphism with a polymerase chain reaction-restriction fragment-length polymorphism-based assay. All study subjects completed a structured questionnaire during an in-person interview. All P values are from two-sided tests. RESULTS We found that 25.1% of the case patients and 21.7% of the control subjects were heterozygous for the Val allele and 3.2% of the case patients and 0. 3% of the control subjects were homozygous for this allele (P =.005). Compared with women with the Ile/Ile genotype, women who had the Ile/Val or Val/Val genotype had an elevated risk of breast cancer (odds ratio [OR] = 1.4; 95% confidence interval [CI] = 1.0-2.0; P =. 05) after adjustment for age, educational level, study period, history of breast fibroadenoma, leisure physical activity, and age at first live birth. The risk was elevated even more among women who were homozygous for the Val allele (OR = 14.1; 95% CI = 1.8-113.4). The association was more pronounced among younger women (</=45 years) than among older women (>45 years). The adjusted OR associated with the Val allele was 1.7 (95% CI = 1.1-2.6) for younger women and 1.0 (95% CI = 0.5-1.9) for older women. CONCLUSIONS Results of this study suggest that polymorphisms of the HER2 gene may be important susceptibility biomarkers for breast cancer risk, particularly among younger women.

[1]  M. Hung,et al.  Direct sequencing analysis of transmembrane region of human neu gene by polymerase chain reaction , 2006, Molecular carcinogenesis.

[2]  X. Shu,et al.  Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  F. Révillion,et al.  ERBB2 oncogene in human breast cancer and its clinical significance. , 1998, European journal of cancer.

[4]  B. Weber,et al.  Recent advances in breast cancer biology. , 1995 .

[5]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[6]  W. Muller,et al.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and cellular biology.

[7]  W. Dougall,et al.  The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. , 1994, Oncogene.

[8]  M. Greene,et al.  neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. , 1993, Pathobiology : journal of immunopathology, molecular and cellular biology.

[9]  K. Hayashi,et al.  Absence of Activating Mutations in the Transmembrane Domain of the c‐erbB‐2 Proto‐oncogene in Human Lung Cancer , 1992, Japanese journal of cancer research : Gann.

[10]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Rajewsky,et al.  G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. , 1991, Nucleic acids research.

[12]  N. Lemoine,et al.  Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. , 1990, Oncogene.

[13]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[14]  D. Weiner,et al.  A point mutation in the neu oncogene mimics ligand induction of receptor aggregation , 1989, Nature.

[15]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[16]  S. Aaronson,et al.  Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene , 1988, Molecular and cellular biology.

[17]  Cori Bargmann,et al.  Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion. , 1988, The EMBO journal.

[18]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[19]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[20]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[21]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[22]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[23]  M. Yoshida,et al.  Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line , 1986, Molecular and cellular biology.

[24]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[25]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[26]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[27]  Charles J. Sherr,et al.  The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF 1 , 1985, Cell.

[28]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[29]  X. Shu,et al.  Urinary excretion of isoflavonoids and the risk of breast cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  B. Weber,et al.  Recent advances in breast cancer biology , 1998, Current opinion in oncology.

[31]  P. Shields,et al.  Molecular epidemiology of breast cancer. , 1997, Progress in clinical and biological research.

[32]  human breast cancer , 2022 .